ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ADMA vs DNLI // GROSS PROFIT MARGIN

ADMA Biologics Inc (NASDAQ) VS. Denali Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ADMA 5 — DNLI 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. DNLI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ADMA DNLI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 57.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 32.90% -35.00% +67.90 ADMA /roic <GO>
EV/EBITDA & P/E Valuation 12.4x — — TIE /valuation <GO>
Free Cash Flow Yield 1.06% -13.67% +14.73 ADMA /fcf-yield <GO>
Operating Margin 37.50% — — TIE /operating-margins <GO>
Net Profit Margin 28.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) 19.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 12.98 10.87 +2.11 ADMA /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 ADMA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 64.1 45.3 +18.80 ADMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 15.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.63B $3.09B -$456.4M DNLI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ADMA REV DNLI REV ADMA GROSS % DNLI GROSS % ADMA FCF DNLI FCF
FY 2025 $510.2M $0 57.4% — $27.8M -$422.1M
FY 2024 $426.5M $0 51.5% — $110.4M -$363.6M
FY 2023 $258.2M $330.5M — — $8.8M -$358.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
DNLI // BETA —